Table 2.
RRs to BMI (<25 and ≥25 kg/m2) in patients receiving abemaciclib + ET and placebo + ET
| RRs | Abemaciclib + ET | Placebo + ET | ||||||
|---|---|---|---|---|---|---|---|---|
| (n = 757) |
(n = 381) |
|||||||
| BMI <25 kg/m2 | BMI ≥25 kg/m2 | OR (95% CI) | P a | BMI <25 kg/m2 | BMI <25 kg/m2 | OR (95% CI) | P a | |
| No. (%) | No. (%) | No. (%) | No. (%) | |||||
| Best overall response | 351 (46.4) | 406 (53.6) | — | — | 172 (45.1) | 209 (54.9) | — | — |
| CR | 6 (1.8) | 17 (4.5) | — | — | 2 (1.2) | 0 (0) | — | — |
| PR | 155 (47.6) | 140 (37.1) | — | — | 33 (19.9) | 61 (30.7) | — | — |
| Stable disease | 145 (44.5) | 189 (50.1) | — | — | 104 (62.7) | 108 (54.3) | — | — |
| PD | 20 (6.1) | 31 (8.2) | — | — | 27 (16.3) | 30 15.1) | — | — |
| NE | 25 | 29 | — | — | 6 | 10 | — | — |
| ORR (CR + PR) | 161 (49.4) | 157 (41.6) | 0.73 (0.54 to 0.99) | .04 | 35 (21.1) | 61 (30.7) | 1.65 (1.02 to 2.67) | .04 |
| Clinical benefit rate (CR + PR + Stable disease) | 306 (93.9) | 346 (91.8) | 0.73 (0.41 to 1.31) | .28 | 139 (83.7) | 169 (84.9) | 1.09 (0.62 to 1.93) | .76 |
a
P values are from the χ2 test (all statistical tests were 2-sided). BMI = body mass index; CI = confidence interval; CR = complete response; ET = endocrine therapy; NE = nonevaluable; OR = odds ratio; ORR = overall response rate; PR = partial response; RR = response rate.